Skip to main content
Equibles

SUPRIYA · Supriya Lifescience Limited

Use SUPRIYA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SUPRIYA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
632.40 INR -9.25 (-1.44%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 10.81K Avg daily vol (3M) 22.93K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close632.40 INR Open643.00 INR Day631.05–645.65 INR 52W close550.85–1,048.35 INR Avg vol 30d24K Last earningsNov 6, 2026 DataDec 2021–Nov 2026

Latest documents

2026
Nov 6
Earnings call
Revenue grew 3.2% as EBITDA margin fell

Supriya Lifescience Limited reported Q2 FY '27 revenue of INR206 crores, up 3.2% year-on-year, while EBITDA was INR45 crores with a 22% margin. It lowered FY '27 EBITDA margin guidance to 23% - 25% due to LATAM regulatory changes, Ambernath ramp-up costs and higher input prices.

7 source passages
Supriya Lifescience Limited For Q2 FY '27, the company reported revenue from operations of INR206 crores as against INR200 crores in Q2 FY '26, a growth of 3.2% year-on-year. EBITDA for the quarter stood at INR45 crores as against INR73 crores in Q2 FY '26 while EBITDA margin stood at 22% for Q2 FY '27. we are revising our EBITDA margin guidance downwards to 23% - 25%. Firstly, the regulatory changes in LATAM market affected demand for some of our higher-margin products. Secondly, we incurred higher operating expenses at our Ambernath facility, which is currently in the ramp-up phase. Thirdly, due to the ongoing war and geopolitical tensions, raw material and solvent prices remained high, which has also impacted on our margins during the quarter. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲32.5% 1.86B INR 467.83M INR '25 Q3 ▲16.4% 1.84B INR 503.82M INR '25 Q4 ▼9.7% 1.45B INR 347.90M INR '26 Q1 ▲20.3% 2.00B INR 504.27M INR '26 Q2 ▲11.2% 2.06B INR 496.75M INR '26 Q3 ▲50.2% 2.77B INR 742.29M INR '26 Q4 ▲30.8% 1.90B INR 240.43M INR '27 Q1 LATEST ▲3.2% 2.06B INR 292.50M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 550.85 INR Now 632.40 INR · 16% Range high 1,048.35 INR
vs 200-day avg -19% vs 50-day avg -27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:SUPRIYA -9.1% -27.5% -17.9% -25.3% -15.7%

Exchange listing

Market
XBOM
Ticker
SUPRIYA
ISIN
INE07RO01027
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.supriyalifescience.com/
Investor relations
https://www.supriyalifescience.com/ir-disclosures-under-regulation-46-of-SEBI-LODR.php

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-09-04 1.00 INR
2025-09-04 1.00 INR
2024-09-20 0.80 INR
2023-09-15 0.60 INR
2022-09-01 0.60 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-06 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-14 Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-28 Audio Transcript
    Supriya Lifescience Limited Q4 FY26 Earnings Conference Call
  • Earnings call · Q3 2026 2026-02-10 Audio Transcript
    Supriya Lifescience Limited Q3 FY '26 Earnings Conference Call